HOME >> BIOLOGY >> NEWS
ChemGenex announces publication confirming activity of Ceflatonin in T315I-Positive CML

MELBOURNE, Australia, and MENLO PARK, California U.S.A. (June 11, 2007). ChemGenex Pharmaceuticals Limited (ASX:CXS and NASDAQ:CXSP) announced today the publication of a report in the prestigious Nature publication Leukemia confirming the positive clinical activity of the company's lead compound, Ceflatonin against Gleevec-resistant, chronic myeloid leukemia (CML) associated with the T315I Bcr-Abl mutation.

The T315I mutation is known to confer resistance to both Gleevec (imatinib mesylate) and second-generation tyrosine kinase inhibitors (dasatinib and nilotinib). Recent publications indicate that the incidence of T315I-associated resistance is increasing and confirm that this mutation is likely to become the prevalent mutation in those who fail tyrosine kinase inhibitor therapy.

The publication by Dr. Laurence Legros of the Hpital Archet, Nice, France and colleagues describes the treatment with Ceflatonin (homoharringtonine, HHT) of a Gleevec-resistant, chronic-phase CML patient with the T315I Bcr-Abl mutation. The authors report that the patient experienced a 50 percent reduction of T315I Bcr-Abl levels within 2.5 months of treatment initiation, and the complete disappearance of the mutation within 5.5 months of treatment. Complete hematological response (CHR) was achieved after three cycles of therapy.

Based on the clinical results, the authors believe that the rapid and complete disappearance of the T315I mutation might suggest a particular sensitivity of this mutation to HHT. The authors conclude that HHT "may provide an alternative therapeutic treatment option for CML patients with the T315I mutation, for whom therapies have been previously lacking."

The authors also noted some hematologic toxicities (neutropenia, thrombocytopenia and anemia), but confirmed that the toxicity of HHT was "easy to manage".

"We are delighted with this publication that reinforces our belief in the potential of Ceflatonin to treat patient
'"/>

Contact: Joan Kureczka
JKureczka@comcast.net
415-821-2413
Kureczka/Martin Associates
11-Jun-2007


Page: 1 2

Related biology news :

1. ChemGenex reports successful personalized dosing of Quinamed at ASCO
2. Almac Diagnostics announces pioneering genetic research on ductal carcinoma in situ
3. ESA announces 2007 award recipients
4. President Bush announces 2005 and 2006 Laureates of National Medals of Science and Technology
5. Conservation Leadership Program announces 2007 awardees
6. ACMG Foundation announces 2007-2008 Luminex/ACMGF award recipient
7. Revolutionary global environment fund announces $50M expansion
8. Biovest announces interim blinded data of fast-tracked pivotal Phase 3 clinical trial of BiovaxID
9. Cell Press announces new partnership with the American Society of Human Genetics
10. Minister Lunn announces $39.6M for next phase of mountain pine beetle response
11. BioMed Central announces new interdisciplinary Biofuels Journal

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/21/2019)... (PRWEB) , ... August 21, 2019 , ... ... E. coli cell line for rapid and low-cost biomanufacturing of complex protein therapeutics, ... Formerly a member of AbSci's Scientific Advisory Board, Dr. Larimore brings more than ...
(Date:8/15/2019)... ... August 15, 2019 , ... Deep Science Ventures ... Food and Agriculture practice, a new unit dedicated to building 100 companies over the ... raw materials and supply chains. , Deep Science Ventures was founded to create ...
(Date:8/14/2019)... ... August 14, 2019 , ... Carterra® ... they have opened a Customer Experience Center (CEC) and office in Munich, Germany. ... office. , The Munich CEC will be a place for researchers throughout Europe ...
Breaking Biology News(10 mins):
(Date:9/4/2019)... N.J. (PRWEB) , ... September ... ... global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, ... Ph.D., Director, Science & Technology will present at the upcoming Nordic Life ...
(Date:8/29/2019)... ... August 28, 2019 , ... DuPont Nutrition & Biosciences ... attendees at the International Baking Industry Expo, September 8 to 11, in booth ... efficiency to cost and waste reduction and from maintaining freshness throughout shelf life ...
(Date:8/27/2019)... ... August 27, 2019 , ... Modality ... announce it has promoted Consulting Engineer, Robert Battista, to Senior Consulting engineer. , ... of onboarding and mentoring new engineers as well as the creation of additional ...
(Date:8/23/2019)... ... August 22, 2019 , ... An ... and is scheduled to broadcast 4Q/2019. Check your local listings for more information. ... for generic drug delivery. Focusing on therapeutics for children and the elderly, viewers ...
Breaking Biology Technology:
Cached News: